BACKGROUND: The aim of the current study was to assess the prognostic value of baseline circulating tumor cells (CTCs) in a large cohort of patients with newly diagnosed metastatic breast cancer (MBC). METHODS: This retrospective study included 185 patients with newly diagnosed MBC evaluated between 2001 and 2007. CTCs were isolated and enumerated before patients started first-line treatment using the CellSearch system. Overall survival (OS) was calculated from the date of CTC measurement, estimated by the Kaplan-Meier product limit method, and compared between groups with the log-rank test. Cox proportional hazards models were fitted to determine the association between CTC levels and OS after controlling for other prognostic factors. RESULTS: The median age of the patients at the time of MBC diagnosis was 49 years. Fifty-six (30.3%) patients presented with de novo metastatic disease, and 129 (69.7%) presented with newly recurrent breast cancer. A total of 114 patients (61.6%) had CTC<5, and 71 (38.4%) had CTC >or= 5. The median OS was 28.3 months and 15 months (P< .0001) for patients with CTC<5 and CTC >or= 5, respectively. Superior survival among patients with CTC<5 was observed regardless of hormone receptor and HER-2/neu status, site of first metastases, or whether the patient had recurrent or de novo metastatic disease. In the multivariate model, patients with CTC >or= 5 had a hazards ratio of death of 3.64 (95% confidence interval, 2.11-6.30) compared with patients with CTC <5. CONCLUSIONS: The results of this large retrospective study confirms that CTCs are a strong independent predictor of survival among women with either de novo or newly recurrent MBC. CTCs should be considered as a new stratification method for women with newly diagnosed MBC.
BACKGROUND: The aim of the current study was to assess the prognostic value of baseline circulating tumor cells (CTCs) in a large cohort of patients with newly diagnosed metastatic breast cancer (MBC). METHODS: This retrospective study included 185 patients with newly diagnosed MBC evaluated between 2001 and 2007. CTCs were isolated and enumerated before patients started first-line treatment using the CellSearch system. Overall survival (OS) was calculated from the date of CTC measurement, estimated by the Kaplan-Meier product limit method, and compared between groups with the log-rank test. Cox proportional hazards models were fitted to determine the association between CTC levels and OS after controlling for other prognostic factors. RESULTS: The median age of the patients at the time of MBC diagnosis was 49 years. Fifty-six (30.3%) patients presented with de novo metastatic disease, and 129 (69.7%) presented with newly recurrent breast cancer. A total of 114 patients (61.6%) had CTC<5, and 71 (38.4%) had CTC >or= 5. The median OS was 28.3 months and 15 months (P< .0001) for patients with CTC<5 and CTC >or= 5, respectively. Superior survival among patients with CTC<5 was observed regardless of hormone receptor and HER-2/neu status, site of first metastases, or whether the patient had recurrent or de novo metastatic disease. In the multivariate model, patients with CTC >or= 5 had a hazards ratio of death of 3.64 (95% confidence interval, 2.11-6.30) compared with patients with CTC <5. CONCLUSIONS: The results of this large retrospective study confirms that CTCs are a strong independent predictor of survival among women with either de novo or newly recurrent MBC. CTCs should be considered as a new stratification method for women with newly diagnosed MBC.
Authors: Marco Wendel; Lyudmila Bazhenova; Rogier Boshuizen; Anand Kolatkar; Meghana Honnatti; Edward H Cho; Dena Marrinucci; Ajay Sandhu; Anthony Perricone; Patricia Thistlethwaite; Kelly Bethel; Jorge Nieva; Michel van den Heuvel; Peter Kuhn Journal: Phys Biol Date: 2012-02-03 Impact factor: 2.583
Authors: R Ramos-Medina; F Moreno; S Lopez-Tarruella; M Del Monte-Millán; I Márquez-Rodas; E Durán; Y Jerez; J A Garcia-Saenz; I Ocaña; S Andrés; T Massarrah; M González-Rivera; M Martin Journal: Clin Transl Oncol Date: 2015-12-08 Impact factor: 3.405
Authors: Kian Behbakht; Michael W Sill; Kathleen M Darcy; Stephen C Rubin; Robert S Mannel; Steven Waggoner; Russell J Schilder; Kathy Q Cai; Andrew K Godwin; R Katherine Alpaugh Journal: Gynecol Oncol Date: 2011-07-12 Impact factor: 5.482
Authors: Siyang Zheng; Henry K Lin; Bo Lu; Anthony Williams; Ram Datar; Richard J Cote; Yu-Chong Tai Journal: Biomed Microdevices Date: 2011-02 Impact factor: 2.838
Authors: Sangjo Shim; Katherine Stemke-Hale; Jamileh Noshari; Frederick F Becker; Peter R C Gascoyne Journal: Biomicrofluidics Date: 2013-01-16 Impact factor: 2.800
Authors: K Ameri; R Luong; H Zhang; A A Powell; K D Montgomery; I Espinosa; D M Bouley; A L Harris; S S Jeffrey Journal: Br J Cancer Date: 2010-01-05 Impact factor: 7.640
Authors: M Mego; U De Giorgi; K Broglio; S Dawood; V Valero; E Andreopoulou; B Handy; J M Reuben; M Cristofanilli Journal: Br J Cancer Date: 2009-11-03 Impact factor: 7.640